Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01894555 · ClinicalTrials.gov registry record · Phase 4
Pharmacogenomics of Antiplatelet Response - II (PARes-II)
A Phase 4 study of Atherothrombosis, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 4
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT01894555: Completed Phase 4 study of Atherothrombosis, sponsored by Johns Hopkins University.
NCT01894555 is a Phase 4 study of Atherothrombosis that has completed, run by Johns Hopkins University. The registered enrollment target is 33 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01894555, a Phase 4 study of Atherothrombosis, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial is examining the effect of 4-week aspirin therapy on platelet transcriptome in persons at high-risk for myocardial infarction or stroke due to family history of early-onset coronary artery disease.
Primary Outcome
Comparison of platelet transcriptome before aspirin therapy with platelet transcriptome after aspirin therapy. The expression levels of genes before aspirin therapy was compared with the expression level of the genes after aspirin therapy. The expression levels were measured using the FPKM unit (Fragments Per Kilobase of transcript per Million mapped reads). The gene with the highest difference (pre vs. post) in FPKM is being reported with name in the units area and the actual difference in the
Conditions Studied
Interventions
- DRUG Aspirin
Study Locations (1)
Maryland
- Johns Hopkins University School of Medicine - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-08 |
| Phase | Phase 4 |
What the finished NCT01894555 record still lists
NCT01894555 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Atherothrombosis appearing as the primary indexed condition, and to 1 intervention - of which Aspirin is the first listed.
NCT01894555 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT01894555 about?
NCT01894555 is a clinical study titled "Pharmacogenomics of Antiplatelet Response - II (PARes-II)". This clinical trial is examining the effect of 4-week aspirin therapy on platelet transcriptome in persons at high-risk for myocardial infarction or stroke due to family history of early-onset coronary artery disease.
What is the current status of trial NCT01894555?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 33 participants. The study started on 2013-01. Estimated completion is 2014-08.
What conditions does trial NCT01894555 study?
This clinical trial studies the following conditions: Atherothrombosis.
What interventions are being tested in trial NCT01894555?
The interventions under investigation include: Aspirin (DRUG).
Who is sponsoring clinical trial NCT01894555?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01894555 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01894555's enrollment target sits among peer trials
33 1528th of 2000 higher than 468 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia